PCM
AKRO

Penserra Capital Management’s Akero Therapeutics AKRO Stock Holding History

Penserra Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-800
Closed -$17K – 1353
2021
Q3 		$17K Buy
800
+5
+0.6% +$113 ﹤0.01% 1271
2021
Q2 		$19K Buy
795
+5
+0.6% +$140 ﹤0.01% 1156
2021
Q1 		$22K Sell
790
-5
-0.6% -$151 ﹤0.01% 957
2020
Q4 		$20K Buy
795
+497
+167% +$13.8K ﹤0.01% 846
2020
Q3 		$9K Buy
+298
New +$10.4K ﹤0.01% 819

Other funds holding AKRO

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Penserra Capital Management's AKRO Position: Q4 2021 in Review

Penserra Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2021, closing a stake of 800 shares — an estimated $17K sold.

Penserra Capital Management first reported a position in AKRO in Q3 2020 and held it in 5 quarters. The position peaked at $22K in Q1 2021. 97 funds tracked by Wall St. Rank hold AKRO as of Q4 2021.

  • Penserra Capital Management reported no remaining Akero Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 800 Akero Therapeutics shares in Q4 2021, an estimated $17K.
  • Penserra Capital Management first reported a position in Akero Therapeutics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Akero Therapeutics position peaked at $22K in Q1 2021.
  • 97 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.